Vertex Pharmaceuticals Inc

2026. g. 22. jūl. 20:06 UTC

Vertex Pharmaceuticals is lower amid market volatility and uncertainty ahead of the Federal Reserve meeting, reflecting a cumulative decline since Tuesday's close.

2026. g. 20. jūl. 18:41 UTC

Vertex Pharmaceuticals shares are lower amid a broader decline in the Biotechnology sector. The company recently completed a $10 billion acquisition to enhance its portfolio.

2026. g. 17. jūl. 18:56 UTC

Vertex Pharmaceuticals shares are declining amid broader market pressures from rising oil prices and inflation concerns linked to military actions in the Gulf region.

2026. g. 16. jūl. 19:51 UTC

Biotechnology stocks are advancing, supporting Vertex Pharmaceuticals' upward movement. This marks a shift from the recent trend of higher daily closes.

2026. g. 15. jūl. 18:36 UTC

Vertex Pharmaceuticals agrees to acquire Crinetics Pharmaceuticals for $85 per share. Shares are higher as analysts view the deal positively amid easing inflation pressures.

2026. g. 14. jūl. 23:16 UTC

Vertex Pharmaceuticals Inc shares are trading lower in after-market hours, continuing a trend of six consecutive daily declines without any specific news to explain the movement.

2026. g. 13. jūl. 19:06 UTC

Vertex Pharmaceuticals announced an agreement to acquire Crinetics for $85 per share, valued at $10 billion, while shares are lower during Monday's session.

2026. g. 10. jūl. 20:02 UTC

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

2026. g. 9. jūl. 23:16 UTC

Vertex Pharmaceuticals shares are lower in after-market trading, with no specific news identified to explain the movement amid broader market sentiment influenced by U.S.-Iran tensions.

2026. g. 8. jūl. 23:46 UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite significant declines in European markets amid geopolitical tensions involving the U.S. and Iran.

2026. g. 7. jūl. 19:36 UTC

Vertex Pharmaceuticals shares are lower today following its $10 billion acquisition of Crinetics Pharmaceuticals, despite analyst support and price target increases.

2026. g. 6. jūl. 23:02 UTC

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

2026. g. 2. jūl. 20:03 UTC

Vertex Pharmaceuticals shares are higher following FDA approval for expanded use of CASGEVY, now available for children as young as 2 years old.

2026. g. 1. jūl. 20:06 UTC

Vertex Pharmaceuticals shares are advancing, reflecting broader market trends. The stock remains above its 20-day moving average despite an earlier session pullback.

2026. g. 30. jūn. 20:07 UTC

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

2026. g. 29. jūn. 19:31 UTC

Vertex Pharmaceuticals is trading higher, driven by positive analyst sentiment and revised earnings estimates ahead of its upcoming earnings report.

2026. g. 26. jūn. 20:04 UTC

Vertex Pharmaceuticals is rising as biotechnology stocks advance during Friday's session. The stock remains above its 20-day moving average after five consecutive higher closes.

2026. g. 25. jūn. 20:02 UTC

Vertex Pharmaceuticals is trading higher today amid notable volatility, reflecting a broader trend since Wednesday's close, despite no specific company news.

2026. g. 24. jūn. 23:26 UTC

Vertex Pharmaceuticals is lower in after-market hours, driven by declines in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

2026. g. 23. jūn. 19:36 UTC

Vertex Pharmaceuticals shares are higher today, recovering from an earlier pullback. The stock remains near the upper end of its one-month trading range.

2026. g. 22. jūn. 20:02 UTC

Vertex Pharmaceuticals is higher today, supported by a diverse pipeline in kidney disease and favorable market conditions following easing U.S.-Iran tensions.

2026. g. 18. jūn. 19:52 UTC

Vertex Pharmaceuticals shares are lower today as biotechnology stocks face pressure. Earlier in the session, shares peaked before reversing direction.

2026. g. 17. jūn. 19:54 UTC

Vertex Pharmaceuticals is rising amid a positive Biotechnology sector trend and favorable Federal Reserve interest rate decisions, boosting investor confidence in healthcare.

2026. g. 16. jūn. 23:16 UTC

Vertex Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment is influenced by optimism over a potential U.S.-Iran peace deal.

2026. g. 15. jūn. 12:46 UTC

Vertex Pharmaceuticals is roughly flat in pre-market hours, maintaining a routine performance and remaining above its 20-day moving average.

2026. g. 12. jūn. 19:36 UTC

Vertex Pharmaceuticals shares are higher today, reflecting stable trading conditions. The stock is positioned above its 20-day moving average, indicating positive market sentiment.

2026. g. 11. jūn. 23:56 UTC

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

2026. g. 10. jūn. 20:03 UTC

Vertex Pharmaceuticals shares are lower as inflation data aligns with forecasts. The stock continues to trade below its 20-day moving average.

2026. g. 9. jūn. 19:56 UTC

Vertex Pharmaceuticals shares are higher during Tuesday's session, having peaked earlier, though they have pulled back slightly. No specific news was identified for this movement.

2026. g. 8. jūn. 19:36 UTC

Vertex Pharmaceuticals shares are lower despite positive data on ALYFTREK for cystic fibrosis. The decline follows broader market dynamics after a strong U.S. jobs report.